Browse > Article
http://dx.doi.org/10.4046/trd.2009.66.1.20

Association between Bone Marrow Hypermetabolism on 18F-Fluorodeoxyglucose Positron Emission Tomography and Response to Chemotherapy in Non-Small Cell Lung Cancer  

Seol, Hee Yun (Department of Internal Medicine, Pusan National University School of Medicine)
Mok, Jeong Ha (Department of Internal Medicine, Pusan National University School of Medicine)
Yoon, Seong Hoon (Department of Internal Medicine, Pusan National University School of Medicine)
Kim, Ji Eun (Department of Internal Medicine, Pusan National University School of Medicine)
Kim, Ki Uk (Department of Internal Medicine, Pusan National University School of Medicine)
Park, Hye-Kyung (Department of Internal Medicine, Pusan National University School of Medicine)
Kim, Seong Jang (Department of Nuclear Medicine, Pusan National University Hospital)
Kim, Yun Seong (Department of Internal Medicine, Pusan National University School of Medicine)
Lee, Min Ki (Department of Internal Medicine, Pusan National University School of Medicine)
Park, Soon Kew (Department of Internal Medicine, Pusan National University School of Medicine)
Publication Information
Tuberculosis and Respiratory Diseases / v.66, no.1, 2009 , pp. 20-26 More about this Journal
Abstract
Background: $^{18}F$-Fluorodeoxyglucose positron emission tomography (FDG-PET) is widely used for the diagnosis and staging of non-small cell lung cancer (NSCLC). The aim of this study is to determine whether the bone marrow hypermetabolism seen on FDG-PET predicts a response to chemotherapy in patients with NSCLC. Methods: We evaluated the patients with advanced NSCLC and who were treated with combination chemotherapy. For determination of the standardized uptake value (SUV) of the bone marrow (BM SUV) on FDG-PET, regions of interest (ROIs) were manually drawn over the lumbar vertebrae (L1, 2, 3). ROIs were also drawn on a homogenous transaxial slice of the liver to obtain the bone marrow/ liver SUV ratio (BM/L SUV ratio). The response to chemotherapy was evaluated according to the Response Evaluation Criteria in Solid Tumor (RECIST) criteria after three cycles of chemotherapy. Results: Fifty-nine NSCLC patients were included in the study. Multivariate analysis was performed using a logistic regression model. The BM SUV and the BM/L SUV ratio on FDG-PET were not associated with a response to chemotherapy in NSCLC patients (p=0.142 and 0.978, respectively). Conclusion: The bone marrow hypermetabolism seen on FDG-PET can not predict a response to chemotherapy in NSCLC patients.
Keywords
Non-small cell lung cancer; Bone marrow; $^{18}F$-Fluorodeoxyglucose positron emission tomography; Chemotherapy;
Citations & Related Records

Times Cited By SCOPUS : 0
연도 인용수 순위
  • Reference
1 Non-small cell lung cancer collaborative group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311:899-909   DOI   PUBMED   ScienceOn
2 Bunn PA Jr. Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why? J Clin Oncol 2002;20:23S-33S   PUBMED
3 Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, et al. American society of clinical oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:330-53   DOI   ScienceOn
4 Vansteenkiste JF, Stroobants SG, Dupont PJ, de Leyn PR, Verbeken EK, Deneffe GJ, et al. Prognostic importance of the standardized uptake value on (18)F-flu-oro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. Leuven lung cancer group. J Clin Oncol 1999;17:3201-6   PUBMED
5 Cobo M, Isla D, Massuti B, Montes A, Sanchez JM, Provencio M, et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 2007;25:2747-54   DOI   ScienceOn
6 Duhaylongsod FG, Lowe VJ, Patz EF Jr, Vaughn AL, Coleman RE, Wolfe WG. Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. Ann Thorac Surg 1995;60:1348-52   DOI   ScienceOn
7 Faneyte IF, Schrama JG, Peterse JL, Remijnse PL, Rodenhuis S, van de Vijver MJ. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer 2003;88:406-12   DOI   ScienceOn
8 Choi JH, Kim HC, Lim HY, Nam DK, Kim HS, Yi JW, et al. Vascular endothelial growth factor in the serum of patients with non-small cell lung cancer: correlation with platelet and leukocyte counts. Lung Cancer 2001;33:171-9   DOI   PUBMED   ScienceOn
9 Cheran SK, Herndon JE 2nd, Patz EF Jr. Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer. Lung Cancer 2004;44:317-25   DOI   ScienceOn
10 Kimura H, Yamaguchi Y, Sun L, Iwagami S, Sugita K. Establishment of large cell lung cancer cell lines secreting hematopoietic factors inducing leukocytosis and thrombocytosis. Jpn J Clin Oncol 1992;22:313-9   PUBMED
11 Pohl G, Rudas M, Taucher S, Stranzl T, Steger GG, Jakesz R, et al. Expression of cell cycle regulatory proteins in breast carcinomas before and after preoperative chemotherapy. Breast Cancer Res Treat 2003;78:97-103   DOI   ScienceOn
12 Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39   DOI   ScienceOn
13 Vesselle H, Schmidt RA, Pugsley JM, Li M, Kohlmyer SG, Vallires E, et al. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res 2000;6:3837-44   PUBMED
14 van Tinteren H, Hoekstra OS, Smit EF, van den Bergh JH, Schreurs AJ, Stallaert RA, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 2002;359:1388-93   DOI   PUBMED   ScienceOn
15 Argiris A, Schiller JH. Can current treatments for advanced non-small-cell lung cancer be improved? JAMA 2004;292:499   DOI   ScienceOn
16 Hoekstra CJ, Paglianiti I, Hoekstra OS, Smit EF, Postmus PE, Teule GJ, et al. Monitoring response to therapy in cancer using [$^{18}$F]-2-fluoro-2-deoxy-D-glucose and positron emission tomography: an overview of different analytical methods. Eur J Nucl Med 2000;27:731-43   DOI   ScienceOn
17 Fujii T, Toyooka S, Ichimura K, Fujiwara Y, Hotta K, Soh J, et al. ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer. Lung Cancer 2008;59:377-84   DOI   ScienceOn
18 Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg 2005;130:151-9   DOI   ScienceOn
19 Weber WA, Ziegler SI, Thodtmann R, Hanauske AR, Schwaiger M. Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med 1999;40:1771-7   PUBMED
20 Korea National Statistical Office. Deaths and death rate by cause. Daejeon: Korea National Statistical Office; 2006
21 Prevost S, Boucher L, Larivee P, Boileau R, Benard F. Bone marrow hypermetabolism on $^{18}$F-FDG PET as a survival prognostic factor in non-small cell lung cancer. J Nucl Med 2006;47:559-65   PUBMED
22 Sasaki R, Komaki R, Macapinlac H, Erasmus J, Allen P, Forster K, et al. [$^{18}$F]Fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 2005;23:1136-43   DOI   ScienceOn
23 Shanafelt TD, Loprinzi C, Marks R, Novotny P, Sloan J. Are chemotherapy response rates related to treatment-induced survival prolongations in patients with advanced cancer? J Clin Oncol 2004;22:1966-74   DOI   ScienceOn
24 Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Nat Cancer Inst 2000;92:205-16   DOI   ScienceOn
25 Buccheri G, Ferrigno D. Prognostic value of stage grouping and TNM descriptors in lung cancer. Chest 2000;117:1247-55   DOI   ScienceOn
26 Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66   DOI   ScienceOn
27 Borges M, Sculier JP, Paesmans M, Richez M, Bureau G, Dabouis G, et al. Prognostic factors for response to chemotherapy containing platinum derivatives in patients with unresectable non-small cell lung cancer (NSCLC). Lung Cancer 1996;16:21-33   DOI   ScienceOn
28 Holdenrieder S, Stieber P, von Pawel J, Raith H, Nagel D, Feldmann K, et al. Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer. Clin Cancer Res 2004;10:5981-7   DOI   ScienceOn
29 Hirsch FR, Varella-Garcia M, Bunn PA Jr, Franklin WA, Dziadziuszko R, Thatcher N, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006;24:5034-42   DOI   ScienceOn
30 Ohtsuka T, Nomori H, Watanabe K, Kaji K, Naruke T, Suemasu K, et al. Prognostic significance of [$^{18}$F]fluorodeoxyglucose uptake on positron emission tomography in patients with pathologic stage I lung adenocarcinoma. Cancer 2006;107:2468-73   DOI   ScienceOn
31 Pieterman RM, van Putten JW, Meuzelaar JJ, Mooyaart EL, Vaalburg W, Koeter GH, et al. Preoperative staging of non-small-cell lung cancer with positronemission tomography. N Engl J Med 2000;343:254-61   DOI   ScienceOn
32 Lee KH, Lee SH, Kim DW, Kang WJ, Chung JK, Im SA, et al. High fluorodeoxyglucose uptake on positron emission tomography in patients with advanced non-small cell lung cancer on platinum-based combination chemotherapy. Clin Cancer Res 2006;12:4232-6   DOI   ScienceOn
33 Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 2001;285:914-24   DOI   ScienceOn
34 Bury T, Dowlati A, Paulus P, Corhay JL, Benoit T, Kayembe JM, et al. Evaluation of the solitary pulmonary nodule by positron emission tomography imaging. Eur Respir J 1996;9:410-4   DOI   ScienceOn
35 Breathnach OS, Freidlin B, Conley B, Green MR, Johnson DH, Gandara DR, et al. Twenty-two years of phase III trials for patients with advanced non-smallcell lung cancer: sobering results. J Clin Oncol 2001;19:1734-42   DOI   PUBMED
36 Sekine I, Tamura T, Kunitoh H, Kubota K, Shinkai T, Kamiya Y, et al. Progressive disease rate as a surrogate endpoint of phase II trials for non-small-cell lung cancer. Ann Oncol 1999;10:731-3   DOI   ScienceOn
37 Verhagen AF, Bootsma GP, Tjan-Heijnen VC, van der Wilt GJ, Cox AL, Brouwer MH, et al. FDG-PET in staging lung cancer: how does it change the algorithm? Lung Cancer 2004;44:175-81   DOI   ScienceOn